NuPathe Inc. Pennsylvania has made an announcement about the acceptance by US FDA to file the company's New Drug Application (NDA) for Zelrix electronic transdermal patch, targeted to treat migraines.
Understanding What Zelrix Offers:
Zelrix is a single-use, transdermal sumatriptan patch intended to provide relief to victims of migraine.
Nausea and fear of vomiting has always deterred migraine patients from consuming oral migraine medications. Since Zelrix need not be administered orally and does not depend upon gastrointestinal absorption, patients may get inspired to be more systematic in using this method of treatment.